Strategic funding DeepCure recently closed a $24M Series A1 round led by IAG Capital Partners, signaling active investor interest and a potential for co-development or strategic partnerships to accelerate clinical milestones.

AI driven platform With an AI-augmented chemistry platform and automation mindset, DeepCure presents a compelling partner for CROs and pharma companies seeking accelerated small molecule discovery and scalable synthesis capabilities.

Clinical timeline The company aims to initiate clinical trials in 2026 for its oral STAT6 and BRD4(BD2) programs, creating near-term collaboration windows around preclinical data, IND preparations, and potential milestone-based deals.

Collaborative momentum Past and ongoing partnerships, including Biosero for automated synthesis and multiple VC investors, indicate openness to co-development, technology licensing, and strategic alliances to expand the platform.

Early stage focus With a small team (11-50 employees) and mid-range revenue signaling growth, there is an opportunity to engage in early-stage partnerships, licensing discussions, and pilot projects that leverage DeepCure’s novel scaffolds and AI-enabled discovery.